First Pharma Pay-for-Delay Cases: General Court upholds the Commission’s Lundbeck decision

13 Sep 2016 | by Imogen Proud and David Gregory

On 8 September 2016, the General Court handed down a series of six much-anticipated judgments upholding the Commission’s 2013 Lundbeck decision, ruling for the first time that pharmaceutical pay-for-delay agreements breach EU competition law (cases T-472/13, T-460/13, T-467/13, T-469/13, T-470/13 and T-471/13).  So-called “pay for delay” agreements typically involve a patent settlement agreement including a payment by the patentee to the generics in exchange for a cessation of patent infringement proceedings and an agreement by the generic companies to stay out of the market for a period of time.

George Peretz QC acted for the European Commission in T-467/13 Arrow v Commission.

Ben Rayment acted for the European Commission in T-471/13 Xellia and Alpharma v Commission.

Ronit Kreisberger and Ligia Osepciu acted for Merck in T-470/13 Merck KGaA v Commission and are acting for Merck in the Paroxetine Appeal in the CAT.

James Bourke acted for the European Commission in Case T-472/13 Lundbeck v Commission, Case T-469/13 Generics (UK) v Commission and Case T-470/13 Merck KGaA v Commission.

Please click here to view the full case note.

The Comment made in this case note are wholly personal and do not reflect the views of any other members of Monckton Chambers, its tenants or clients.